Funding Received
$0 in 1 Round from 2 Investors
Most Recent Funding
Series A on October 31, 2013 / Undisclosed Amount
Founded:
2013
Headquarters:
San Francisco, CA
Description:
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel
Categories:
Biotechnology
Website:
http://alector.com

Detailed Description

Update

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Current Team (1)

Update

Funding Rounds (1) - $0.00

Update

Investors (2)

Update
  • B1ce9d2887c930e2d5d82b64a7eebcb9

    OrbiMed Advisors

    OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
  • Aktht4eq1boptqctfosv

    Polaris Partners

    Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...

Offices/Locations (1)

Update
  • Office

    953 Indiana Street

    San Francisco, CA 94107

    USA

Images (1)

Update
  • Baeb92aa7d2d1ee41a1ebc1f751e9146